initial public offerings (IPOs) trading on American exchanges

Thursday, February 6, 2014

Genocea Biosciences (GNCA) began trading on the NASDAQ on 5 February 2014

The Cambridge, Mass.-based company is developing vaccines to treat the herpes simplex virus, malaria and other diseases. It raised $66 million after offering 5.5 million shares for $12 per share. It plans to use the money raised to pay for drug research and development. The shares are listed on the Nasdaq under the ticker symbol "GNCA." They fell $1, or 8.3 percent, to $11.


Cambridge Discovery Park 5th Floor, 100 Acorn Park Driv
United States

Genocea Biosciences, Inc. is a United States-based clinical-stage company that develops T cell vaccines. The Company utilizes T cell immunity to develop the next generation of vaccines. It designs vaccines using ATLAS, its technology platform. It identifies T cell antigens to induce immune responses. Its pipeline of T cell vaccines includes a clinical-stage therapeutic candidate in HSV-2, GEN-003, as well as earlier-stage programs in Pneumococcus, Chlamydia, HSV-2 prophylaxis and Malaria. Its platform develops vaccines and immunotherapies for a range of infectious diseases, cancers and autoimmune diseases.

No comments:

Post a Comment